https://scholars.lib.ntu.edu.tw/handle/123456789/594191
標題: | The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group | 作者: | El Bairi, Khalid Haynes, Harry R Blackley, Elizabeth Fineberg, Susan Shear, Jeffrey Turner, Sophia de Freitas, Juliana Ribeiro Sur, Daniel Amendola, Luis Claudio Gharib, Masoumeh Kallala, Amine Arun, Indu Azmoudeh-Ardalan, Farid Fujimoto, Luciana Sua, Luz F Liu, Shi-Wei HUANG-CHUN LIEN Kirtani, Pawan Balancin, Marcelo El Attar, Hicham Guleria, Prerna Yang, Wenxian Shash, Emad I-CHUN CHEN Bautista, Veronica Do Prado Moura, Jose Fernando Rapoport, Bernardo L Castaneda, Carlos Spengler, Eunice Acosta-Haab, Gabriela Frahm, Isabel Sanchez, Joselyn Castillo, Miluska Bouchmaa, Najat Md Zin, Reena R Shui, Ruohong Onyuma, Timothy Yang, Wentao Husain, Zaheed Willard-Gallo, Karen Coosemans, An Perez, Edith A Provenzano, Elena Ericsson, Paula Gonzalez Richardet, Eduardo Mehrotra, Ravi Sarancone, Sandra Ehinger, Anna Rimm, David L Bartlett, John M S Viale, Giuseppe Denkert, Carsten Hida, Akira I Sotiriou, Christos Loibl, Sibylle Hewitt, Stephen M Badve, Sunil Symmans, William Fraser Kim, Rim S Pruneri, Giancarlo Goel, Shom Francis, Prudence A Inurrigarro, Gloria Yamaguchi, Rin Garcia-Rivello, Hernan Horlings, Hugo Afqir, Said Salgado, Roberto Adams, Sylvia Kok, Marleen Dieci, Maria Vittoria Michiels, Stefan Demaria, Sandra Loi, Sherene |
關鍵字: | TUMOR-INFILTRATING LYMPHOCYTES; NEOADJUVANT CHEMOTHERAPY; PROGNOSTIC-SIGNIFICANCE; PREDICTIVE-VALUE; FREE SURVIVAL; TRASTUZUMAB; SUBTYPES; MICROENVIRONMENT; IDENTIFICATION; ASSOCIATION | 公開日期: | 1-十二月-2021 | 出版社: | NATURE PORTFOLIO | 卷: | 7 | 期: | 1 | 來源出版物: | NPJ breast cancer | 摘要: | The advent of immune-checkpoint inhibitors (ICI) in modern oncology has significantly improved survival in several cancer settings. A subgroup of women with breast cancer (BC) has immunogenic infiltration of lymphocytes with expression of programmed death-ligand 1 (PD-L1). These patients may potentially benefit from ICI targeting the programmed death 1 (PD-1)/PD-L1 signaling axis. The use of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarkers has been under intense examination. Emerging data suggest that TILs are associated with response to both cytotoxic treatments and immunotherapy, particularly for patients with triple-negative BC. In this review from The International Immuno-Oncology Biomarker Working Group, we discuss (a) the biological understanding of TILs, (b) their analytical and clinical validity and efforts toward the clinical utility in BC, and (c) the current status of PD-L1 and TIL testing across different continents, including experiences from low-to-middle-income countries, incorporating also the view of a patient advocate. This information will help set the stage for future approaches to optimize the understanding and clinical utilization of TIL analysis in patients with BC. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/594191 | ISSN: | 2374-4677 | DOI: | 10.1038/s41523-021-00346-1 | SDG/關鍵字: | atezolizumab; cisplatin; cyclophosphamide; doxorubicin; durvalumab; epirubicin; lapatinib; letrozole; nivolumab; pembrolizumab; programmed death 1 ligand 1; programmed death 1 receptor; tamoxifen; trastuzumab; breast cancer; circulating tumor cell; cost effectiveness analysis; human; lymphocytic infiltration; middle income country; Review; triple negative breast cancer; tumor associated leukocyte |
顯示於: | 病理學科所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。